BGI was founded in 1999 as a research organization to support the Human Genome Project. Over the years, BGI¡¯s in-house research has contributed to the development of the field of Genomics in significant ways, as evidenced by a wealth of peer-reviewed publications in prestigious scientific journals. Today, BGI is actively participating in the fields of Cancer Research, Bio-sustainability and Personalized Medicine through a global network of collaborators.
BGI Genomics is the world¡¯s leading provider of genomic, BGI gene test and proteomic services, now serving customers in more than 66 countries. We provide academic institutions, pharmaceutical co***nies, health care providers and other organizations with integrated genomic and proteomic services and solutions across a broad range of applications ***nning basic and translational research, drug discovery, agriculture and health care.
To provide these services, we operate a large network of service Laboratories in China, Hong Kong, the US and Europe. Our customers benefit from the highest level of sequencing experience in the world to support their research and drug discovery projects. Our service laboratories operate under strict internationally recognized quality systems, such as those from CAP and ISO.
More recently, BGI developed and launched its own DNBseq&©|8482; sequencing technology, based on DNA Nanoball sequencing technology that was invented in our Complete Genomics research facility in Silicon Valley, California. Scientists around the world now rely on DNBseq NGS services for the highest quality data at the lowest cost. |
Home
